

Welcome Reception, plus Exhibit and Poster Setup at the Mead Center     MONDAY - MARCH 10, 2014     7:00 am - 8:00 am   Registration and Breaktast in the Exhibit Area, plus Exhibit and Poster Setup     8:00 am - 8:00 am   Viral Vectors and Vaccines Reheasal Studio Wereb Speaker Abstracts & Bios   Viral Vectors and Vaccines Reheasal Studio Wereb Speaker Abstracts & Bios   Viral Vectors and Vaccines Reheasal Studio Wereb Speaker Abstracts & Bios   Viral Vectors and Vaccines Reheasal Studio Wereb Speaker Abstracts & Bios     8:30 am -9:15 am   Danalt Larvis, PhD - Investy of Wyoning Advanced Recombinant Okyopatein Production the Based Marces (Hancer Statut Budger Statut Statut Budger Statut Budger Statut Budger Stat		SUNDAY • MARCH 9, 2014			
MONDAY - MARCH 10, 2014     7:00 am - 8:00 am   Registration and Breakfast in the Exhibit Area, plus Exhibit and Poster Setup     8:00 am - 8:30 am   Viral Vectors and Vaccines Rehearsal Studio     8:30 am - 9:15 am   Baculovirus Expression Technology Kogod Cradle   Viral Vectors and Vaccines Rehearsal Studio     8:30 am - 9:15 am   Donald L Jarvis, PPD - University of Wyoming Amond Recombinand Gyopoto Posicion in the Baculovirus insect 68 System   Viral Vectors and Vaccines Repeared Wine Vector Abstracts & Bios     9:15 am - 10:00 am   Amine A. Kame, PDD - McGill University - Hubp Cell Desity Insect Cell Calture as New Generation Process for Manufacturing Viral Vector and Vaccine Process for Manufac	3:30 pm – 6:30 pm	Welcome Reception, plus Exhibit and Poster Setup at the Mead Center			
7.00 am – 8:00 am   Meeting Overview in Gogod Cradle     8:00 am – 8:30 am   Viral Vectors and Vaccines Kogod Cradle     8:00 am – 8:10 am   Viral Vectors and Vaccines Kogod Cradle     8:00 am – 9:15 am   Onald L Jarvis, PhD - University of Wyoning Kogod Cradle   Viral Vectors and Vaccines & Bios     8:30 am – 9:15 am   Onald L Jarvis, PhD - University of Wyoning Kogod Cradle   Viral Vectors and Vaccines & Bios     9:15 am – 10:00 am   Release A Straters & Bios   Vorance encloped PhD - Macil University - High Call University - Hi		MONDAY • MARCH 10, 2014			
Botol or - 8:30 am   Interception of a constraint	7:00 am – 8:00 am	Registration and Breakfast in the Exhibit Area, plus Exhibit and Poster Setup			
Baculovirus Expression Technology Verw Speaker Abstracts & Bios     Viral Vectors and Vaccines Rehearal Studio Verw Speaker Abstracts & Bios       8:30 am - 9:15 am     Daniel L. Jarris, F. Dh- University of Words Baculovirus-insect Cell System     Rherry L. Matech, MY - VIII National Institute eff Abstracts & Bios     Norme Genzel, Ph D- Mac, Phack-Institute for View Speaker Abstracts & Bios     Norme Genzel, Ph D- Mac, Phack-Institute for View Speaker Abstracts & Bios     Norme Genzel, Ph D- Mac, Phack-Institute for View Speaker Abstracts & Bios     Norme Genzel, Ph D- Mac, Phack-Institute for View Speaker Abstract Sectors Phack-Institute for View Speaker Abstracts & Bios     Norme Genzel, Ph D- Mac, Phack-Institute for View Speaker Abstract Sectors Phack-Institat Sectors Phack-Institute for View Speaker Abstract Sectors Phac	8:00 am – 8:30 am	Meeting Overview in Kogod Cradle			
8:30 am - 9:15 am   Danald L Jarvis, PhD - University of Wyoming Advanced Recombinant Bycognotem Production in the Advanced Recombinant Bycognotem Production See CRIS Potential Interprete Unit Semi CRIS from Advanced Privapolet Biolity Insect CRI CRIS from Advanced Privapolet Biolity Insect Private Biol Advanced Privapolet Biolity Insect Private Biol Advanced Privapolet Biolity Insect Private Biolity Insect Private Biol Advanced Privapolet Biolity Insect Private Biol Advanced Privapolet Biolity Insect Private Biol Advanced Privapolet Biolity Private Biol Advanced Privapolet Biol Biol Biol Advanced Privapolet Biol Biol Biol Biol Biol Biol Biol Biol		Baculovirus Expression Technology Kogod Cradle <u>View</u> Speaker Abstracts & Bios	<b>Cellular Therapies</b> Classroom <u>View Speaker Abstracts &amp; Bios</u>	Viral Vectors and Vaccines Rehearsal Studio View Speaker Abstracts & Bios	
9:15 am - 10:00 am   Amine A. Kamen, PhD - McGill University - High Cell Density Insect Cell Culture as a New Generation (Cell Density Insect Cell Culture as a New Generation Process for Manufacturing Vira Vectors and Voccess Market Science Cell Culture as a New Generation (Cell Density Insect Cell Culture as a New Generation News Science Cell Culture as a New Generation (Cell Density Insect Cell Culture as a New Generation News Science Cell Culture as a New Generation (Cell Density Insect Cell Culture as a New Generation Norming Break in the Exhibit Area   Robert M. Science Phor Voyage Therapeutics Progress Report on Systemic Delivery of rANP-UJ (Cent in the Goden Retriever Muscular Dystrophy Asses Quality Attributes     10:00 am - 11:00 am 11:00 am - 11:20 am 11:00 am - 11:20 nm on 11:30 am - 12:00 nm on 11:30 am - 2:15 pm   Indev R   Indev R     11:00 am - 2:15 pm   Gale E. Smith, PhD - Novayax, Inc Development of an Insect Cell Derived Influenca A(H7H9) Virus-Like Particle CVLP Vacine: From Gene to Man   Madhusudan V. Peshwa, PhD - MaxCyte Inc. Translational Development of Masser Cell Derived Influenca A(H7H9) Virus-Like Particle CVLP Vacine: From Gene to Man   Delake A. Gavin, PhD - FDA CBER Regulatory Considerations for Adeno-Alsociated Unce-Innumberapies     2:15 pm - 3:00 pm   Loy E. Volkman, PhD - University of California, Hyperceyression   Delake A. Mamen, PhD - McGill University Attenson Break in the Exhibit Area     3:00 pm - 3:30 pm   Arifa S. Khan, PhD - FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Manufacturing and Properties   Mainee A. Kamen, PhD - MCGill University Attenson Break in the Exhibit Area     3:00 pm - 5:30 pm   Charles Richardson, P	8:30 am – 9:15 am	<b>Donald L. Jarvis, PhD</b> • University of Wyoming Advanced Recombinant Glycoprotein Production in the Baculovirus-Insect Cell System	Harry L. Malech, MD • NIH National Institute of Allergy and Infectious Diseases (NIAID) – Generation of Neutrophils and Monocytes from Induced Pluripotent Stem Cells: Potential Therapeutic Utility	<b>Yvonne Genzel, PhD •</b> Max-Planck-Institute for Dynamics of Complex Technical Systems – New Cell Substrates for Virus and Viral Vector Production	
10:00 am - 10:30 amMorning Break in the Exhibit Area10:30 am - 11:30 amInDevR11:00 am - 11:30 amTechnology Workshops:Expression Systems, LLCBIA Separations11:30 am - 12:00 noonInDevRNovasep12:00 noon - 1:30 pmLunch in the Exhibit Area (Poster Presentations from 1:00 pm - 1:30 pm)1:30 pm - 2:15 pmGale E. Smith, PhD - Novavax, Inc Development of an insect Cell Derived Influenza A(H7N9) Virus-Like Arricle (VLP) Vaccine: From Gene to ManMadhusudan V. Peshwa, PhD - MaxSyte Inc. Translational Development of an insect Cell Derived Influenza A(H7N9) Virus-Like Arricle (VLP) Vaccine: From Gene to ManMadhusudan V. Peshwa, PhD - MaxSyte Inc. Translational Development of Anseen Cell Derived Influenza A(H7N9) Virus-Like Arricle (VLP) Vaccine: From Gene to ManMadhusudan V. Peshwa, PhD - MaxSyte Inc. Translational Development of Anseen Cell Derived Influenza A(H7N9) Virus-Like Arricle (VLP) Vaccine: From Gene to ManDale Ando, MD - Sangano BioSciences, Inc. Reconstituting HIV Immunity with CGS Modified Autologus CD4 T Cells to Eradicate HIVAmine A. Kamen, PhD - McGill University Artigens and Expression Systems Comparison3:00 pm - 3:30 pmArrifa S. Khan, PhD - FDA CBER SubstratesRacheil Ofir, PhD - Phize-Phied Phier Pacultaria Like ParticlesVictor Lip PhD - The Childres for Huand Influenza Victor Manufacturing and Properties4:15 pm - 5:00 pmCharles Richardson, PhD - Takeda Pharmacuticals SubstratesPrice L Levine, PhD - University of Pennstyknain Lip Mater Artarian Gene Vector Vaccines Finaede Philaelphia - Advancing Gene Therapy Product CMC Huand Ise Reception in Kogot Crafte: Potential and Prifalls for Cellular, VLP, and Gene Vector Vaccines 	9:15 am – 10:00 am	<b>Amine A. Kamen, PhD •</b> McGill University – <i>High</i> <i>Cell Density Insect Cell Culture as a New Generation</i> <i>Process for Manufacturing Viral Vectors and Vaccines</i>	<b>Jessica L. Lo Surdo, PhD</b> • FDA CBER Toward Improved Characterization of Stem Cells for Use in Cellular Therapies: Quantitative Approaches to Better Assess Quality Attributes	<b>Robert M. Kotin, PhD</b> • Voyager Therapeutics Progress Report on Systemic Delivery of rAAV9-U7 Vector in the Golden Retriever Muscular Dystrophy Canine Model of Duchenne Muscular Dystrophy	
10:30 am - 11:00 am   InDevR     11:00 am - 11:30 am   Technology Workshops:   Expression Systems, LLC   BIA Separations     11:30 am - 12:00 noon   Novasep     12:00 noon - 1:30 pm   Lunch in the Exhibit Area (Poster Presentations from 1:00 pm - 1:30 pm)     1:30 pm - 2:15 pm   Gale E. Smith, PhD - Novavax, Inc Development of an Insect Cell Derived Influenza A(H7M9) Wirus-Like Particle (VLP) Vaccine: From Gene to Man   Madhusudan V. Peshwa, PhD - MaxCyte Inc. Translational Development of Messenger RNA Encoded Chineric Antigen Receptor Engineered Onco-Immunotherapies   Denise K. Gavin, PhD - FDA CBER Regulatory Considerations for Adeno-Associated Wiruses     2:15 pm - 3:00 pm   Loy E. Volkman, PhD - University of California, Berkeley - The University and Englenzed Onco-Immunotherapies   Dela Ando, MD - Sagman BioSciences, Inc. Reconstituting HVI Immunity with ICS Modified Autologous CD4 T Cells to Eradicate HIV   Indieen X Kamen, PhD - McGill University Influenza Micro Manufacturing Technologies: Antigens and Expression Systems Comparison     3:00 pm - 3:30 pm   Arifa S. Khan, PhD - FDA CBER (Substrates   Reconstituting HVI Immunity with ICS Modified Autologous CD4 T Cells to Eradicate HIV   Replection In Vaccine Cell     4:15 pm - 5:00 pm   Charles Richardson, PhD - Takeda Pharmaceuticals US.A., Inc Scale-Up and Manufacturing of Norvirus Virus-Like Particles   Bruce L. Levine, PhD - University of Pennsylvania US.A., Inc Scale-Up and Manufacturing of Norvirus Virus-Like Particles   J. Fraser Wright, PhD - The Childres' Hospital of Thuor	10:00 am – 10:30 am	Morning Break in the Exhibit Area			
11:00 am - 11:30 am   Technology Workshops:   Expression Systems, LLC   BiA Separations     11:30 am - 12:00 noon   Novasep     12:00 noon - 1:30 pm   Lunch in the Exhibit Area (Poster Presentations from 1:00 pm - 1:30 pm)     1:30 pm - 2:15 pm   Gale E. Smith, PhD • Novaxa, Inc Development of an Insect Cell Derived Influenza A(H7M9) Virus-Like Particle (VLP) Vaccine: From Gene to Man   Madhusudan V. Peshwa, PhD • MaxCyte Inc. Translational Development of Messenger RNA Encoded Chimeric Antigen Receptor Engineered Onco-Immunotherapies   Denise K. Gavin, PhD • DA CBER Regulatory Considerations for Adeno-Associated Viruses     2:15 pm - 3:00 pm   Loy E. Volkman, PhD • University of California, Berkeley - The Twist to Baculowirus Replication and Hyperexpression   Dale Ando, MD • Sangamo BioSciences, Inc. Reconstituting HVI nummity with CCBS Modified Autologaus CDA T Cells to Endiduce HIV   Amine A. Kamen, PhD • McGill University Influenza Vaccine Manifacturing Technologies: Antigen and Expression Systems Comparison     3:30 pm - 4:15 pm   Arifa S. Khan, PhD • EDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Pluvistem Therapeutics Inc. PLX, Placental-Derived Adherent Stromal Cells - Manufacturing of Properties   Victor Lu, PhD • FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals US.A., Inc Scale-Up and Manufacturing of Norvirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania UJ.A., Inc Scale-Up and Manufacturing of Norvirus Virus-Like	10:30 am – 11:00 am		Aldevron	InDevR	
11:30 am - 12:00 noon   Novasep     12:00 noon - 1:30 pm   Lunch in the Exhibit Area (Poster Presentations from 1:00 pm - 1:30 pm)     1:30 pm - 2:15 pm   Gale E. Smith, PhD - Novavax, Inc Development of an Insect Cell Derived Influenza A(H7N9) Virus-Like Particle (VLP) Vaccine: From Gene to Man   Madhusudan V. Peshwa, PhD - MaxCyte Inc. Translational Development of Messenger NNA Encode Chimeric Artigen Receptor Engineered Onco-Immunotherapies   Denise K. Gavin, PhD - FDA (BER Regulatory Considerations for Adeno-Associated Viruses     2:15 pm - 3:00 pm   Loy E. Volkman, PhD - University of California, Berkeley - The Iwist to Bacalovirus Replication and Pached Chimeric Artigen Receptor Engineered   Amine A. Kamen, PhD - McGill University Influenza Vaccine Manufacturing Technologies: Antigens and Expression Systems Comparison     3:00 pm - 3:30 pm   Artfa S. Khan, PhD - FDA CBER Challenges of Novel Virus Detection in Vaccine Cell   Racheli Ofir, PhD - Pluristem Therapeutics Inc. PLX, Placental-Derived Adherent Stromal Cells – Manufacturing Stress Comparisons of Lentiviral Vectors for Manufacturing of Novel Virus Detection in Vaccine Cell   Sito pm - 5:00 pm   Lister Stichardson, PhD - Takeda Pharmaceuticals   Erecept California, Bruce L. Levine, PhD - University of Pennsylvania, Cliner CAR Delivery and Clinical Update: Strong Lost - Advancing Gene Therapy Product CMC Through Late Stage Clinical Development Update: California, Bruce L. Levine, PhD - University of Pennsylvania, Cliner Challenges of Novel Virus Detection in Kogod Crade: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines   Sito pm - 5:45 pm   Panel Discussion in Kogod Crade: Potential and Pitfalls for Cel	11:00 am – 11:30 am	Technology Workshops:	Expression Systems, LLC	BIA Separations	
12:00 noon - 1:30 pm   Lunch in the Exhibit Area (Poster Presentations from 1:00 pm - 1:30 pm)     1:30 pm - 2:15 pm   Gale E. Smith, PhD • Novavax, Inc Development of an Insect Cell Derived Influenza A(H7N9) Virus-Like Particle (VLP) Vaccine: from Gene to Man   Madhusudan V. Peshwa, PhD • MaxCyte Inc. Translational Development of Messenger RNA Encoded Chimeric Antigan Receptor Engineered Onco-Immunotherapies   Denise K. Gavin, PhD • FDA CBER Regulatory Considerations for Adeno-Associated Virus es     2:15 pm - 3:00 pm   Loy E. Volkman, PhD • University of California, Berkeley - The Twist to Baculovirus Replication and Hyperexpression   Dale Ando, MD • Sangamo BioSciences, Inc. Reconstituting HV Immunity with CCR5 Modified Autologous CD4 T Cells to Eradicate HIV   Amine A. Kamen, PhD • McGill University Influenza Vaccine Manufacturing Technologies: Antigens and Expression Systems Comparison     3:00 pm - 3:30 pm   Arifa S. Khan, PhD • FDA (BER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Plun'etter Therapeutics Inc. Manufacturing and Properties   Victor Lu, PhD • FDA (BER Challenges of Novel Virus Detection in Vaccine Cell Substrates     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals USA, Inc Scale-Up and Manufacturing of Norovirus Drateed Against Cancer: CAR Delivery and Clinical Update   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia - Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm - 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines     • Daniel Takefman	11:30 am – 12:00 noon			Novasep	
1:30 pm - 2:15 pm   Gale E. Smith, PhD • Novavax, Inc. – Development of an Insect Cell Derived Influenza A(H7M9) Virus-Like Particle (VLP) Vaccine: From Gene to Man   Madhusudan V. Peshwa, PhD • MaxCyte Inc. Translational Development of Messenger RNA Berkeley – The Twist to Baculovirus Replication and Hyperexpression   Denise K. Gavin, PhD • FDA CBER Regulatory Considerations for Adeno-Associated Droc-Immunotherapies     2:15 pm - 3:00 pm   Loy E. Volkman, PhD • University of California, Berkeley – The Twist to Baculovirus Replication and Hyperexpression   Dale Ando, MD • Sangamo BioSciences, Inc. Reconstituting HIV Immunity with CCR5 Modified Autologous CD4 T Cells to Eradicate HIV   Amine A. Kamen, PhD • McGill University Influenza Vaccine Manufacturing Technologies: Antigens and Expression Systems Comparison     3:00 pm - 3:30 pm   Arifa S. Khan, PhD • FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Pluristem Therapeutics Inc. PL, Placental-Derived Adherent Stromal Cells – Manufacturing and Properties   Victor Lu, PhD • FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania Chimeric Antigen Receptor (CAR) Modified T Cells Torageted Against Cancer: CAR Delivery and Clinical   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia – Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm - 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines	12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Presentations from 1:00 pm – 1:30 pm)			
2:15 pm - 3:00 pm   Loy E. Volkman, PhD • University of California, Berkeley - The Twist to Baculovirus Replication and Hyperexpression   Dale Ando, MD • Sangamo BioSciences, Inc. Reconstituting HIV Immunity with CCR5 Modified Autologous CD4 T Cells to Eradicate HIV   Amine A. Kamen, PhD • McGill University Influenza Vaccine Manufacturing Technologies: Antigens and Expression Systems Comparison     3:00 pm - 3:30 pm   Arrifa S. Khan, PhD • FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Pluristem Therapeutics Inc. PLX, Placental-Derived Adherent Stromal Cells - Manufacturing and Properties   Victor Lu, PhD • FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals U.S.A., Inc Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania Chimeri Antigen Receptor (CAR) Modified T Cells Targeted Against Cancer: CAR Delivery and Clinical Update   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia - Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm - 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines • Daniel Takefman, PhD • FDA CBER • Robin A. Robinson, PhD • FDA HHS • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm - 8:00 pm   6:00 pm - 8:00 pm   Reception in the Exhibit Area	1:30 pm – 2:15 pm	<b>Gale E. Smith, PhD</b> • Novavax, Inc. – Development of an Insect Cell Derived Influenza A(H7N9) Virus-Like Particle (VLP) Vaccine: From Gene to Man	<b>Madhusudan V. Peshwa, PhD •</b> MaxCyte Inc. Translational Development of Messenger RNA Encoded Chimeric Antigen Receptor Engineered Onco-Immunotherapies	<b>Denise K. Gavin, PhD •</b> FDA CBER Regulatory Considerations for Adeno-Associated Viruses	
3:00 pm - 3:30 pm   Afternoon Break in the Exhibit Area     3:30 pm - 4:15 pm   Arifa S. Khan, PhD • FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Pluristem Therapeutics Inc. PLX, Placental-Derived Adherent Stromal Cells - Manufacturing and Properties   Victor Lu, PhD • FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals U.S.A., Inc Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania Chimeric Antigen Receptor (CAR) Modified T Cells Targeted Against Cancer: CAR Delivery and Clinical Update   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia - Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm - 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines • Daniel Takefman, PhD • FDA CBER • Robin A. Robinson, PhD • FDA CBER • Robin Levis, PhD • FDA CBER     6:00 pm - 8:00 pm   6:00 pm - 8:00 pm	2:15 pm – 3:00 pm	<b>Loy E. Volkman, PhD •</b> University of California, Berkeley – The Twist to Baculovirus Replication and Hyperexpression	<b>Dale Ando, MD •</b> Sangamo BioSciences, Inc. Reconstituting HIV Immunity with CCR5 Modified Autologous CD4 T Cells to Eradicate HIV	<b>Amine A. Kamen, PhD •</b> McGill University Influenza Vaccine Manufacturing Technologies: Antigens and Expression Systems Comparison	
3:30 pm - 4:15 pm   Arifa S. Khan, PhD • FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates   Racheli Ofir, PhD • Pluristem Therapeutics Inc. PLX, Placental-Derived Adherent Stromal Cells – Manufacturing and Properties   Victor Lu, PhD • FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use     4:15 pm - 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia – Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm – 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines     • Daniel Takefman, PhD • FDA CBER • Robin A. Robinson, PhD • FDA HHS   • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm – 8:00 pm   Reception in the Exhibit Area	3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area			
4:15 pm – 5:00 pm   Charles Richardson, PhD • Takeda Pharmaceuticals U.S.A., Inc. – Scale-Up and Manufacturing of Norovirus Virus-Like Particles   Bruce L. Levine, PhD • University of Pennsylvania Chimeric Antigen Receptor (CAR) Modified T Cells Targeted Against Cancer: CAR Delivery and Clinical Update   J. Fraser Wright, PhD • The Children's Hospital of Philadelphia – Advancing Gene Therapy Product CMC Through Late Stage Clinical Development     5:00 pm – 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines     • Daniel Takefman, PhD • FDA CBER   • Robin Levis, PhD • FDA CBER     • Robin A. Robinson, PhD • FDA HHS   • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm – 8:00 pm   Reception in the Exhibit Area	3:30 pm – 4:15 pm	<b>Arifa S. Khan, PhD •</b> FDA CBER Challenges of Novel Virus Detection in Vaccine Cell Substrates	<b>Racheli Ofir, PhD</b> • Pluristem Therapeutics Inc. <i>PLX, Placental-Derived Adherent Stromal Cells</i> – <i>Manufacturing and Properties</i>	<b>Victor Lu, PhD •</b> FDA CBER Regulatory Considerations for Lentiviral Vectors for Human Use	
5:00 pm – 5:45 pm   Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines     • Daniel Takefman, PhD • FDA CBER   • Robin Levis, PhD • FDA CBER     • Robin A. Robinson, PhD • FDA HHS   • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm – 8:00 pm   Reception in the Exhibit Area	4:15 pm – 5:00 pm	<b>Charles Richardson, PhD</b> • Takeda Pharmaceuticals U.S.A., Inc. – <i>Scale-Up and Manufacturing of Norovirus Virus-Like Particles</i>	<b>Bruce L. Levine, PhD</b> • University of Pennsylvania Chimeric Antigen Receptor (CAR) Modified T Cells Targeted Against Cancer: CAR Delivery and Clinical Update	<b>J. Fraser Wright, PhD</b> • The Children's Hospital of Philadelphia – Advancing Gene Therapy Product CMC Through Late Stage Clinical Development	
• Daniel Takefman, PhD • FDA CBER   • Robin Levis, PhD • FDA CBER     • Robin A. Robinson, PhD • FDA HHS   • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm - 8:00 pm   Reception in the Exhibit Area	5:00 pm – 5:45 pm	Panel Discussion in Kogod Cradle: Potential and Pitfalls for Cellular, VLP, and Gene Vector Vaccines			
• Robin A. Robinson, PhD • FDA HHS   • Phillip B. Maples, PhD • Laurus Bio, LLC     6:00 pm - 8:00 pm   Reception in the Exhibit Area		Daniel Takefman, PhD • FDA CBER     • Robin Levis, PhD • FDA CBER			
6:00 pm – 8:00 pm Reception in the Exhibit Area		Robin A. Robinson, PhD • FDA HHS Phillip B. Maples, PhD • Laurus Bio, LLC			
	6:00 pm – 8:00 pm	Reception in the Exhibit Area			

ISBioTech 4th Spring Meeting (continued): TUESDAY • MARCH 11, 2014					
	Baculovirus Expression Technology Kogod Cradle	Cellular Therapies Classroom	Viral Vectors and Vaccines Rehearsal Studio		
7:30 am – 8:30 am	Breakfast in the Exhibit Area				
8:30 am – 9:15 am	<b>Gary W. Blissard, PhD</b> • Boyce Thompson Institute for Plant Research – The Interplay Among Genomes of the Baculovirus AcMNPV and the Host Cell Line Tnms42 at the Transcriptome Level	<b>Kelvin G.M. Brockbank, PhD</b> • Cell and Tissue Systems, Inc. – 3D Preservation of Natural Tissues and Engineered Constructs	<b>Axel Schambach, MD, PhD •</b> Hannover Medical School – Biosafety Challenges for Use of Retro- and Lentiviral Vectors in Gene Therapy		
9:15 am – 10:00 am	Gorben P. Pijlman, PhD • Wageningen University Baculovirus Production of Enveloped Virus-Like Particle Vaccines	Harry C. Ledebur, Jr., PhD • Axonia Medical, Inc. Stretch Growth of Tissue-Engineered Nerve Grafts	<b>Cécile Bauche, PhD •</b> THERAVECTYS SA Lentiviral-Based Anti-HIV Therapeutic Vaccine: Design, Preclinical Studies, and Phase I/II Clinical Trial Preliminary Results		
10:00 am – 10:30 am	Morning Break in the Exhibit Area				
10:30 am — 11:15 am	<b>Renée Lapointe, PhD</b> • Sylvar Technologies Inc. The Use of Evolutionary and Pathogenesis Studies in the Registration of Baculovirus-Based Insect Control Products	<b>Ian K. McNiece, PhD</b> • MD Anderson Cancer Center Development of Autologous and Allogeneic Stem Cell Products for Clinical Therapies	<b>Douglas J. Jolly, PhD •</b> Tocagen Inc. Production of a Replicating Retroviral Vector for Clinical Use		
11:15 am — 12:00 noon	<b>Robert Boulanger, PhD</b> • Protein Sciences Corporation – Start-Up to Scale-Up in 100 Days: Rapid Modification of an Existing Microbial Fermentation Facility for Influenza Vaccine Production	<b>Fred Miesowicz, PhD</b> • Argos Therapeutics, Inc. Clinical Development of Autologous Dendritic Cells for Active Immunotherapy: The Challenges and Promise in Metastatic Renal Cell Carcinomas	<b>Patric S. Lundberg, PhD •</b> Eastern Virginia Medical School – <i>Genetics, the Forgotten Variable</i>		
12:00 noon – 12:45 pm	AAV Baculovirus	s Reference Material Working Group Meeting i	in the Classroom		
12:45 pm – 6:00 pm	Free Afternoon with Recommended Activities				
6:00 pm – 9:00 pm	"South Paci	<i>fic"</i> Banquet at the Mead Center in the Molly <b>S</b>	Smith Study		
	WEDNESDAY • MARCH 12, 2014				
7:30 am – 8:30 am	Breakfast in the Exhibit Area				
8:30 am – 9:15 am	<b>Shu Wang, PhD</b> • National University of Singapore Baculoviral Transduction for Cellular Reprogramming and Stable Genetic Modification of Human Pluripotent Stem Cells	Mary Pat Moyer, PhD • INCELL Corporation, LLC New Cell Therapies, Tools, and Product Pipelines	Jacek Lubelski, PhD • uniQure B.V. Insect Cell Based AAV Production: An Update on Process Optimizations		
9:15 am – 10:00 am	<b>Christopher W. Kemp, PhD</b> and <b>April Birch</b> • Kempbio, Inc. – Advances in the Use of BacMam Transduced Mammalian Cells for the Large-Scale Expression of Proteins and Virus-Like Particles	<b>Brian Niland, PhD •</b> FDA CBER Characterization of Cellular Therapies: Regulatory Considerations	James Miskin, PhD • Oxford BioMedica plc Lentiviral Vectors: Summary of Experience Gained from Multiple Clinical Trials		
10:00 am – 10:30 am	Morning Break in the Exhibit Area				
10:30 am — 11:15 am	Yu-Chen "Andy" Hu, PhD • National Tsing Hua University, Taiwan – Baculovirus as a Tool for Vaccine Development	<b>David F. Stroncek, MD</b> • NIH Clinical Center, Department of Transfusion Medicine <i>Recent Advances in Adoptive T Cell Therapy</i>	<b>Mercedes Segura, PhD •</b> bluebird bio Inc. Overview of Downstream Processing Strategies for Lentiviral Vectors		
11:15 am — 12:00 noon	<b>Thera Mulvania, PhD</b> • Expression Systems, LLC Purification of Recombinant Baculovirus by End Point Dilution and gp64 Screening	<b>Andrew Picken, PhD</b> - Loughborough University Minimizing Cryopreservation Risks for Stem Cell Therapy Bioprocessing	Vladimir A. Slepushkin, MD, PhD • Lentigen Corporation – <i>Qualification of Lot Release Assays for</i> <i>Lentiviral Vectors</i>		
12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Presentations from 1:00 pm – 1:30 pm)				
1:30 pm – 2:15 pm	<b>Dominic Esposito, PhD</b> • Leidos Biomedical Research, Inc. – Improved Baculovirus Technologies for Protein Production in the Insect Cell Expression System	<b>Thomas A. Brieva, PhD</b> • Celgene Cellular Therapeutics – <i>Designing Scalable Processes for Cell</i> <i>Therapies</i>	Mark J. Federspiel, PhD • Mayo Clinic – Novel Production and Purification Processes for Oncolytic Viruses		
2:15 pm – 3:00 pm	Holly J. Popham, PhD • AgBiTech – Development and Agricultural Use of Baculoviruses	Phillip B. Maples, PhD • Laurus Bio, LLC Cancer Vaccines / Immunotherapy Approaches	John T. Gray, PhD • St. Jude Children's Research Hospital – <i>Clinical Grade Lentiviral Vector Production</i> from Stable Cell Lines		
3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area (Exhibit and Poster Teardown begins at 3:30 pm)				
3:30 pm – 4:15 pm	<b>Kari Airenne, PhD</b> • University of Eastern Finland, A.I. Virtanen Institute – <i>Baculovirus Receptors and</i> <i>Signaling in Mammalian Cells</i>	<b>Margarida Serra, PhD</b> • iBET – Integrating Bioprocess Optimization and Omics Tools Towards the Design of Novel Stem Cell Therapies for Cardiac Repair	<b>Christine Le Bec, PhD •</b> Généthon Analytical Methods to Measure Full and Empty AAV Particles		
4:15 pm – 5:00 pm	<b>Otto-Wilhelm Merten, PhD</b> • Généthon Towards Large-Scale AAV Vector Production — The Use of Insect Cell/Baculovirus Technology: Developments, Optimisations, and Perspectives	Heather L. Brown • Cord Blood Registry Collection, Processing, and Storage of Umbilical Cord Blood Stem Cells			
5:00 pm	Meeting Adjourns				